Pfizer filed a lawsuit against fellow pharmaceutical giant Johnson & Johnson (J&J) over “anticompetitive practices” in a go-for-the-throat showdown involving the drug industry’s treatment of medicines that are similar to the originals, but don’t have the same exact active components.
Pfizer accused J&J of “exclusionary contracts” and price manipulation “to maintain its monopoly” for a drug used to treat rheumatoid arthritis, Crohn’s disease and other afflictions.
The brawl between Pfizer and J&J centers on the competition between J&J’s Remicade and Pfizer’s biosimilar alternative, Inflectra, which launched in late 2016.
Pfizer alleged that J&J threatened to withhold rebates from insurers that had determined Inflectra was an acceptable medical alternative to Remicade. The threats, Pfizer alleged, caused insurers to reverse course.
J&J also offered discounts on Remicade to healthcare providers in exchange for their pledge not to carry Inflectra, Pfizer alleged.
“These anticompetitive practices are preventing physicians from trying and patients from accessing the biosimilar,” Pfizer said in a statement.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Former Novartis Executive Sentenced to Probation for Role in Generic Drug Price-Fixing Scheme
May 16, 2024 by
CPI
NCAA Faces Bankruptcy Threat from Antitrust Lawsuits
May 16, 2024 by
CPI
K&L Gates Expands Antitrust Practice with New Partners
May 15, 2024 by
CPI
Polish Regulators Probe PS Store and Steam for Antitrust Violations
May 15, 2024 by
CPI
French Regulator Meat-Cutting Sector Case Following Antitrust Review
May 15, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI